HOUSTON, March 23, 2020 /PRNewswire/ -- Soliton,
Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
the results from its pivotal cellulite trial will be now be
presented at the AAD 2020 Annual Meeting, to now be held virtually
in the next 6-8 weeks.
The Company received notice on Friday,
March 20, 2020, that The American Academy of Dermatology
(AAD), which was recently forced to cancel their annual dermatology
conference due to the coronavirus (COVID-19), is making plans to
conduct their conference through a digital event highlighting
content that would have been presented at the annual meeting.
Soliton's previously accepted oral presentation regarding its
pivotal cellulite clinical trial results is expected be presented
in a pre-recorded webcast by Dr. Elizabeth
Tanzi, the lead investigator on the trial and member of
Soliton's Scientific Advisory Board. Details for the virtual
presentation will be announced in the coming weeks.
"We are excited and appreciative that the American Academy of
Dermatology has planned to host their Annual Meeting virtually this
year. We are thankful for the opportunity to share with the
physician and dermatology community Soliton's pivotal results
regarding the potential of the RAP device to improve the appearance
of cellulite," stated Christopher
Capelli, MD, founder, President and CEO of Soliton.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in clinical and preclinical testing, including the
potential to improve the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth and the potential to treat keloid and hypertrophic
scars by targeting the stiffened environment in the intracellular
matrix.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to announce
results from the cellulite pivotal study. These statements
relate to future events, future expectations, plans and prospects.
Although Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Soliton has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our SEC filings, including under the heading "Item 1A. Risk
Factors" in the Form 10-K for year ended December 31, 2019 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-to-present-pivotal-cellulite-clinical-trial-results-at-virtual-aad-2020-annual-meeting-301027932.html
SOURCE Soliton, Inc.